Maze Therapeutics announced on May 1st an exclusive worldwide licensing agreement with Sanofi for MZE001, an oral substrate reduction therapy in development for the treatment of Pompe disease that recently completed a Phase 1 clinical trial in healthy volunteers.
Under the terms of the agreement, Maze will receive a $150 million payment consisting of both upfront cash and future equity investment for the rights to further develop and commercialize MZE001, as well as an exclusive license to related GYS1-targeting back-up programs and intellectual property. Maze will be eligible to receive up to an additional approximately $600 million in potential development, regulatory and sales milestones, as well as meaningful royalties on sales if MZE001 is successfully commercialized.
This would seem to be great news for Maze, and should ensure that the next phase of clinical trials will begin in the near future. We may see clinical centres in the UK offering the chance to join the study and so please look out for further updates on our website and social media.
For the full press release, please follow this link:
Maze Therapeutics announces exclusive worldwide licence agreement with Sanofi for MZE001
